CFD RESEARCH CORPORATION SBIR Phase II Award, May 2023
A SBIR Phase II contract was awarded to CFD Research Corporation in May, 2023 for $548,493.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
All edits
Edits on 3 Mar, 2024
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+447 characters)
CFD RESEARCH CORPORATION SBIR Phase II Award, May 2023
Article
Abstract
This project seeks to develop a new broad-spectrum antiviral drug against viruses from the Bunyavirales family. These viruses have been designated as being among the highest potential to cause the next pandemic. CFD Research is advancing a natural product-derived antiviral chemistry that has demonstrated strong in vitro potency against Bunyaviruses with low cytotoxicity. We seek to produce an optimized lead candidate from this project.
Infobox
Is a
SBIR/STTR Award Recipient
Government Agency
Government Branch
Award Type
SBIR0
Contract Number (US Government)
W911SR-23-C-00140
Award Phase
Phase II0
Award Amount (USD)
548,4930
Date Awarded
May 15, 2023
0End Date
May 18, 2025
0Official Website
Find more entities like CFD RESEARCH CORPORATION SBIR Phase II Award, May 2023
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.